Please assess the completion status of the following clinical trial:

Trial Title: Combined Anticancer Treatment of Advanced Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Synchronous or metachronous peritoneal carcinomatosis arising from histologically proven colorectal or appendiceal adenocarcinoma~* Complete macroscopic cytoreduction (CCR-0/1)~* Free treatment interval of at least 6 month after the last chemotherapy~* Age over 18 and below 71 years~* Good general health status (Karnofsky \> 70%, ECOG 0-2)~* Absence of hematogenous metastasis (lung, bone, brain, \> 3 peripheric resectable liver metastases)~* Absence of contraindication for systemic chemotherapy and/or extended surgery~* Life expectancy greater than 6 months~* Written informed consent~* Creatinine clearance \> 50 ml/min, serum creatinine ≤ 1.5 x ULN~* Serum bilirubin ≤ 1.5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2.5 x ULN~* Platelet count \> 100,000 /ml, haemoglobin \> 9 g/dl, neutrophile granulocytes ≥ 1,500 /ml, International Normalized Ration (INR) ≤ 2~* Absence of peripheral neuropathy \> grade 1 (CTCAE v4.0)~* No pregnancy or breast feeding. Adequate contraception in fertile patients.~Exclusion Criteria:~* Incomplete cytoreduction~* Hematogenous metastasis including irresectable liver metastasis~* Prior chemotherapy or therapy with EGFR receptor antibody for metastatic disease~* K-ras mutation~* Known allergy to murine or chimeric monoclonal antibodies~* Histology of signet ring carcinoma~* Other malignancy than disease under study / second cancer~* Impaired liver, renal or hematologic function as mentioned above (inclusion criteria)~* Heart failure NYHA ≥ 2 or significant Coronary Artery Disease~* Alcohol and/or drug abuse~* Patients unable or unwilling to comply with the study protocol, treatment or follow-up~* Patients included in other clinical trials interfering with the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): 1. FOLFOX/FOLFIRI + cetuximab (6 cycles)~2. CRS and HIPEC~3. FOLFOX/FOLFIRI + cetuximab (6 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).